Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

Mid-Afternoon Market Update: Crude Oil Up Over 3%; Lumber Liquidators Shares Spike Higher

Benzinga.com  June 17, 2016

GlycoMimetics Announces Pricing of Public Offering of Common Stock

Business Wire June 17, 2016

GlycoMimetics Announces Proposed Public Offering of Common Stock

Business Wire June 16, 2016

GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia

Business Wire June 13, 2016

GlycoMimetics Reports GMI-1271 Phase 1/2 Data: Showed Overall Response Rate 47% Among 19 Patients

Benzinga.com  June 10, 2016

GlycoMimetics’ GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML

Business Wire June 10, 2016

GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia

Business Wire June 6, 2016

GlycoMimetics to Present at Jefferies 2016 Healthcare Conference

Business Wire June 2, 2016

GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine

Business Wire May 25, 2016

Initial Efficacy Data for GlycoMimetics’ GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress

Business Wire May 19, 2016

GlycoMimetics Reports First Quarter 2016 Results

Business Wire May 4, 2016

GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference

Business Wire April 25, 2016

GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors

Business Wire March 21, 2016

GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016

Business Wire March 17, 2016

GlycoMimetics Announces Initial Clinical Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients

Business Wire March 2, 2016

GlycoMimetics to Present at Cowen and Company's 36th Annual Health Care Conference

Business Wire March 1, 2016

GlycoMimetics Reports Fourth Quarter and Year-End 2015 Results

Business Wire February 29, 2016

GlycoMimetics to Present at 18th Annual BIO CEO & Investor Conference

Business Wire February 1, 2016

GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model

Business Wire December 7, 2015

GlycoMimetics Highlights Preclinical Data in Oral Presentation at ASH Meeting Demonstrating Impact of GMI-1271 on T Memory Stem Cells

Business Wire December 7, 2015